Literature DB >> 2402772

The use of tri(n-butyl)phosphate detergent mixtures to inactivate hepatitis viruses and human immunodeficiency virus in plasma and plasma's subsequent fractionation.

M P Piët1, S Chin, A M Prince, B Brotman, A M Cundell, B Horowitz.   

Abstract

The treatment of plasma with organic solvent/detergent mixtures at the time of plasma collection or pooling could reduce the exposure of technical staff to infectious viruses and enhance the viral safety of the final product. Treatment of plasma for 4 hours with 2-percent tri(n-butyl)phosphate (TNBP) at 37 degrees C, with 1-percent TNBP and 1-percent polyoxyethylensorbitan monooleate (Tween 80) at 30 degrees C, or with 1-percent TNBP and 1-percent polyoxyethylene ethers, (Triton X-45) at 30 degrees C resulted in the rapid and complete inactivation of greater than or equal to 10(4) tissue culture-infectious doses (TCID50) of vesicular stomatitis and Sindbis viruses, which are used as surrogates. Treatment of plasma with TNBP and TNBP and Tween-80 was shown to inactivate greater than or equal to 10(4) TCID50 of human immunodeficiency virus. TNBP treatment of plasma contaminated with 10(6) chimpanzee-infectious doses (CID50) of hepatitis B virus and 10(5) CID50 of non-A,non-B hepatitis virus prevented the transmission of hepatitis to chimpanzees. Immediately after treatment of plasma with 2-percent TNBP, the recovery of factors VIII, IX, and V and antithrombin III was 80, 90, 40, and 100 percent, respectively. Recovery of all factors was greater than or equal to 90 percent after treatment with TNBP and detergent mixtures. Treated plasma was fractionated by standard techniques into antihemophilic factor and prothrombin complex concentrates, immune globulin, and albumin. Prior treatment with TNBP or TNBP and detergent did not affect the separations of desired proteins. Therefore, it appears possible to inactivate viruses in plasma before the execution of standard fractionation procedures.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2402772     DOI: 10.1046/j.1537-2995.1990.30790385516.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  7 in total

Review 1.  Evolution of recombinant factor VIII safety: KOGENATE and Kogenate FS/Bayer.

Authors:  Jeanne M Lusher; Inge Scharrer
Journal:  Int J Hematol       Date:  2009-11-03       Impact factor: 2.490

2.  Human Immunodeficiency Virus (HIV).

Authors: 
Journal:  Transfus Med Hemother       Date:  2016-05-09       Impact factor: 3.747

3.  In vivo evaluation of the cross-genotype neutralizing activity of polyclonal antibodies against hepatitis C virus.

Authors:  Philip Meuleman; Jens Bukh; Lieven Verhoye; Ali Farhoudi; Thomas Vanwolleghem; Richard Y Wang; Isabelle Desombere; Harvey Alter; Robert H Purcell; Geert Leroux-Roels
Journal:  Hepatology       Date:  2011-02-11       Impact factor: 17.425

4.  Octagam 5%, an intravenous IgG product, is efficacious and well tolerated in subjects with primary immunodeficiency diseases.

Authors:  Hans D Ochs; Paul J Pinciaro
Journal:  J Clin Immunol       Date:  2004-05       Impact factor: 8.317

Review 5.  Blood protein derivative viral safety: observations and analysis.

Authors:  B Horowitz
Journal:  Yale J Biol Med       Date:  1990 Sep-Oct

6.  Use of humanised rat basophilic leukaemia cell line RS-ATL8 for the assessment of allergenicity of Schistosoma mansoni proteins.

Authors:  Daniel Wan; Fernanda Ludolf; Daniel G W Alanine; Owen Stretton; Eman Ali Ali; Nafal Al-Barwary; Xiaowei Wang; Michael J Doenhoff; Adriano Mari; Colin M Fitzsimmons; David W Dunne; Ryosuke Nakamura; Guilherme C Oliveira; Marcos J C Alcocer; Franco H Falcone
Journal:  PLoS Negl Trop Dis       Date:  2014-09-25

7.  SARS-coronavirus (SARS-CoV) and the safety of a solvent/detergent (S/D) treated immunoglobulin preparation.

Authors:  H F Rabenau; L Biesert; T Schmidt; G Bauer; J Cinatl; H W Doerr
Journal:  Biologicals       Date:  2005-04-07       Impact factor: 1.856

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.